News at CenExel

Global Raters’ Work Stress and Task Burnout

Global Raters’ Work Stress and Task Burnout:An Empirical Exploration of Our Primary Endpoint Evaluators Written by: Elan A. Cohen,1 Judy Montero,2Vera M. Grindell,3 Katarzyna Wyka,4 Howard A. Hassman,1David P. Walling,3  Cassie L. Blanchard,1Mark G. Opler,5David...

Validation of a suite of ERP and QEEG biomarkers

Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers   Written by: M. Cecchi a,*, M. Adachi b, A. Basile c, D.L. Buhl d, H. Chadchankar e, S. Christensen f, E. Christian g,...

A link between seizure and stuttering disorders?

CenExel is proud to announce that the work of David Walling, PhD, CEO and Principal Investigator at CenExel CNS, joined lead author, John H Krystal, as co-author of the recent Cerevel Therapeutics study titled, Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial, published in The Lancet.

Karuna Positive Results on Phase 3 EMERGENT-3 Trial of KarXT

CenExel is proud to announce that the work of David Walling, PhD, CEO and Principal Investigator at CenExel CNS, joined lead author, John H Krystal, as co-author of the recent Cerevel Therapeutics study titled, Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial, published in The Lancet.

CenExel Partnerships to Fight COVID-19

MIAMI, Jul. 27, 2020 – Dr. Howard Schwartz, Chief Medical Officer and Principal Investigator for vaccine trials at Research Centers of America (RCA), a CenExel Center of Excellence, participated in a roundtable discussion today with U.S. Vice President Mike Pence,...